We help personalize treatment recommendations for the depressed patie...


Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

Brainify at a Glance

Brainify is a diagnosis support tool leveraging AI/ML software to aid depression screening and treatment for improved diagnostic accuracy and treatment outcomes.

Our platform allows clinicians to examine their patients based on their biological data, such as electroencephalography (EEG) and electrocardiography (ECG).


Subjective Diagnostics

The standard method of depression diagnosis in the majority of mental health clinics involves the use of criteria found in the DSM-5 or other self-reported measures.

Unfortunately, these measures are prone to the subjectivity of both professionals and patients.

Diagnosis & Treatment

Brainify’s precision treatment approach utilizes electroencephalogram (EEG) technology – an effective, non-invasive method of studying brain activity – to enable evidence-based diagnosis and treatment of depression.

Our technology examines underlying neurological brain activity, including brain circuits, brain networks and connectivity patterns, utilizing the RDoC approach developed by the National Institute of Mental Health.

Because no two brains are alike, Brainify changes the paradigm from “one-size-fits-all” to a more personalized approach, enabling improved treatment based on factors such as age and sex.

How Brainify Works

Traction & Accomplishments 

Brainify’s evidence-based solution is backed by two decades of scientific research in psychiatry, neuroscience, and psychopharmacology. 

The Brainify team has developed several AI and ML models (age–prediction model, sex phenotype prediction model, artifact-removal model) now capable of examining 4 EEG biomarkers using the latest data-science technologies from 2018 onward.

To maintain our competitive edge, the technology undergirding the Brainify platform will be patent protected, with filings planned for Q1 2022.

Brainify has secured $425K in funding to-date from angel investors.

Our Greatest Asset: The Brainify Team

Ivan Mishanin
CEO & Co-founder
Ivan is an entrepreneur with 20 years of experience in tech. He sold a previous startup for >$50M to Zurich Insurance.

Mariam Khayretdinova
Chief Scientific Officer & Co-founder
Mariam is a neuroscientist with 8+ years of experience in the tech industry.

Alex Shovkun, Ph.D.
Chief AI Officer
Alex is a data scientist with 15 years of expertise in mathematical modeling, including those for diagnostic medical solutions.  

Martijn Arns, Ph.D.
Science Advisor
Martijn is the founder of the Brainclinics research institute and author of more than 200 scientific publications. 

Diego A. Pizzagalli, Ph.D.
Science Advisor
Professor Pizzagalli is the founding director of the Center for Depression, Anxiety, and Stress Research at Harvard Medical School. 

Lana Graf, Ph.D.
Lana is Principal on Artificial Intelligence at the International Finance Corporation (IFC)/ World Bank Group.

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.

Request Access


No updates yet.


No backers yet.

Quick Signup TBD

You must have an account to do this!

the platform

Copyright © 2019 All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.